1. Screening for Multiple Endocrine Neoplasia Type 1 and Hormonal Production in Apparently Sporadic Neuroendocrine Tumors1
- Author
-
Frédéric Troalen, Eric Baudin, Martin Schlumberger, Thierry Debaere, Jean-Michel Bidart, Jacques Ropers, Pierre Ruffié, Jean-Christophe Sabourin, Philippe Rougier, Etienne Comoy, Vladimir Lazar, Philippe Lasser, and Michel Ducreux
- Subjects
endocrine system ,medicine.medical_specialty ,Hyperparathyroidism ,endocrine system diseases ,Pituitary disease ,business.industry ,Endocrinology, Diabetes and Metabolism ,Biochemistry (medical) ,Clinical Biochemistry ,Neuroendocrine tumors ,medicine.disease ,Biochemistry ,Endocrinology ,Somatostatin ,Calcitonin ,Internal medicine ,Medicine ,MEN1 ,business ,Multiple endocrine neoplasia ,hormones, hormone substitutes, and hormone antagonists ,Hormone - Abstract
Screening was performed in 130 consecutive patients with apparently sporadic neuroendocrine tumors (NET) to assess the prevalence of multiple endocrine neoplasia type 1 (MEN1) and hormonal production. Screening for MEN1 included measurement of serum calcium and PTH[ PTH-(1–84)], gastrin, PRL, and insulin-like growth factor type I (IGF-I) levels. MEN1 genetic testing was performed in patients with two components of the MEN1 syndrome. Screening for hormonal production included measurement of serum neuron-specific enolase (NSE), calcitonin (CT), glycoprotein α-subunit (GPα), hCG β-subunit (free hCGβ), and somatostatin levels. Twenty-four-hour urinary free cortisol (UFC) and 5-hydroxyindolacetic acid (5-HIAA) determinations were also performed. Four patients had hyperparathyroidism, none of whom had pituitary or familial disease. Hyperprolactinemia was compatible with a pituitary disease in one patient. No acromegalic feature or any increase in IGF-I was found. Hypergastrinemia, compatible with an associated ...
- Published
- 1999
- Full Text
- View/download PDF